NKX2.5 is expressed in papillary thyroid carcinomas and regulates differentiation in thyroid cells

Ricardo Cortez Cardoso Penha 1,2, Luisa Aguirre Buexm 2, Fabiana Resende Rodrigues 3, Taciana Padilha de Castro 4, Maria Carolina S. Santos 3, Rodrigo Soares Fortunato 5, Denise P. Carvalho 1, Luciene C. Cardoso-Weide 3 and Andrea C. F. Ferreira 1,6*

Abstract

Background: NKX2.5 is a transcription factor transiently expressed during thyroid organogenesis. Recently, several works have pointed out the oncogenic role of NKX2.5 in a variety of tumors. We therefore hypothesized that NKX2.5 could also play a role in thyroid cancer.

Methods: The validation of NKX2.5 expression was assessed by immunohistochemistry analysis in a Brazilian case series of 10 papillary thyroid carcinoma (PTC) patients. Then, the long-term prognostic value of NKX2.5 and its correlation with clinicopathologic features of 51 PTC patients was evaluated in a cohort with 10-years follow-up (1990–1999). Besides, the effect of NKX2.5 overexpression on thyroid differentiation markers and function was also investigated in a non-tumor thyroid cell line (PCCL3).

Results: NKX2.5 was shown to be expressed in most PTC samples (8/10, case series; 27/51, cohort). Patients who had tumors expressing NKX2.5 showed lower rates of persistence/recurrence (p = 0.013). Overexpression of NKX2.5 in PCCL3 cells led to: 1) downregulation of thyroid differentiation markers (thyrotropin receptor, thyroperoxidase and sodium-iodide symporter); 2) reduced iodide uptake; 3) increased extracellular H2O2 generation, dual oxidase 1 mRNA levels and activity of DuOx1 promoter.

Conclusions: In summary, NKX2.5 is expressed in most PTC samples analyzed and its presence correlates to better prognosis of PTC. In vitro, NKX2.5 overexpression reduces the expression of thyroid differentiation markers and increases ROS production. Thus, our data suggests that NKX2.5 could play a role in thyroid carcinogenesis.

Keywords: NKX2.5, Thyroid cancer, Persistence/recurrence, Papillary thyroid carcinoma, Differentiation, Iodide uptake, H2O2

Background

The homeodomain transcription factor NKX2.5 is critical for differentiation and proliferation of the primitive pharyngeal endodermal cells [1], being expressed up to the embryonic day 11.5 in the mouse thyroid primordium [2]. However, NKX2.5 expression is discontinued just before the appearance of proteins that are crucial for thyroid hormone biosynthesis, such as thyroglobulin (Tg), thyroperoxidase (TPO), thyrotropin receptor (TSHR), sodium-iodide symporter (NIS) and dual oxidases (DuOx1 and 2) [2–4].

Even though NKX2.5 expression seems to be restricted to heart in adults [5], NKX2.5 has been described to be expressed in several types of tumors, including pediatric acute lymphoblastic leukemia [6], skin squamous cell carcinoma [7] and ovarian yolk sac tumor [8]. However, the possible role of NKX2.5 in thyroid cancer remains elusive.

Thus, in the present work, we aimed at evaluating NKX2.5 expression by immunohistochemistry in 10 PTC samples. To assess NKX2.5 association with clinical prognostic, we have also included 51 patients from a
well-characterized 10 years Brazilian cohort of PTC patients [9]. We have also investigated the functional role of this transcription factor on the expression of thyroid differentiation markers and reactive oxygen species (ROS) production in normal thyroid cells (PCCL3). To our knowledge, this is the first study showing NKX2.5 expression in PTC samples.

**Methods**

**Patients**
To validate the expression of NKX2.5, we have included 10 patients admitted to the hospital in 2012, with the diagnosis of PTC, according to the International Classification of Diseases for Oncology (ICD-O) 80,503 (papillary thyroid carcinoma) in the register of the Cancer Hospital from the centre’s database. The eligible patients were submitted to thyroid surgery to treat PTC and were aged 18 years or more at the time of surgery.

To assess NKX2.5 association with clinical prognostic, we have also included 51 patients [9] admitted to the hospital between January 1st, 1990, and December 31st, 1999, with a diagnosis of PTC as per the International Classification of Diseases for Oncology (ICD-O) codes 83,403, 82,603 or 80,503 (follicular variant of PTC, thyroid papillary adenocarcinoma (SOE), papillary thyroid carcinoma, respectively) in the register of the Cancer Hospital from the centre’s database, which was available in 2010. The eligible patients had undergone thyroidectomy as a type of thyroid surgical approach to treat PTC in the study period and were aged 18 years or more at time of initial surgery.

The three main outcome variables of interest were persistence, recurrence and PTC-free status. For this classification, we have only considered the first event experienced by the patient. Another outcome studied was death as a result of PTC and/or from any other cause.

**PTC persistence** was defined as evident residual disease (active disease) until 12 months after initial surgical treatment. Furthermore, PTC recurrence was defined as having the first event of active disease occurring between 1 and 10 years of follow-up. Patients were considered PTC-free if they did not show active disease after the initial surgery, in the period between the initial surgery and ten years of follow-up. Active PTC disease was defined when one or more of the following was observed: (a) structural disease evidenced by positive imaging findings or after radioactive iodine ($^{131}$I, RAI) therapy; and (b) biochemical evidence of disease, with significant increase in serum thyroglobulin (Tg) levels during thyroid hormone treatment (levothyroxine, LT4) compared with previously stable levels and/or an increase in serum Tg levels after LT4 withdrawal (stimulated Tg). The clinicopathologic information in each case, including age, gender, treatment, pathologic stage and presence or absence of tumor recurrence or persistence, was obtained from medical records and tumor registries. The characteristics of the 51 patients selected for this study are summarized in Table 1.

**Immunohistochemistry analysis**

Immunohistochemistry (IHC) analysis was performed on paraffin sections of the papillary thyroid carcinomas mounted on glass slides. Tissue sections of heart necropsy, obtained from the “Departamento de Patologia da Universidade Federal Fluminense”, served as NKX2.5 positive control. For antigen retrieval, the slides were incubated in a pH 6.0 solution (target antigen retrieval solution) for 45 min in a water bath, at 96 °C, followed by a washing step with phosphate-buffered saline (PBS). Incubations with the primary antibody against NKX2.5 (polyclonal anti-NKX2.5, SAB2101601, Sigma-Aldrich; diluted 1:800) were performed overnight at 4 °C. Samples were then incubated with biotinylated secondary antibodies using the streptavidin-biotin-peroxidase kit (Strep ABC complex/HRP Duet kit, DAKO Cytomation). The reactions were developed with a solution containing diaminobenzidine tetrahydrochloride chromogen, and the sections were counterstained with Harris’s hematoxylin. Negative and positive controls were included in all reactions.

All the sections were assessed independently by two pathologists, who met to resolve discordant interpretations and establish a consensus categorization. A binary classification (positive vs. negative) was used to score the IHC. The positive slides were evaluated semi-quantitatively by the distribution of the immunohistochemical positivity (1–49% and 50–100%) of neoplastic cells. Whenever the distribution was <50%, the cases were classified as low expression, and cases with ≥50% of cells stained were classified as high expression. Positive slides were also classified according to the subcellular distribution of NKX2.5 in cytoplasmic and nuclear.

**Cell culture**

The non-tumoral rat thyroid cell line (PCCL3) was kindly donated by dr. Fusco, from the Department of Molecular Medicine and Medical Biotechnology, Naples University, who developed this cell line. PCCL3 was maintained in Coon’s modified Ham’s F-12 medium (HiMedia Laboratories, Mumbai, India), supplemented with 5% FBS and a six-hormone mixture (1 mU/ml TSH, 10 μg/ml insulin, 5 μg/ml transferrin, 10 nM hydrocortisone, 10 ng/ml somatostatin, and 10 ng/ml glycy-l-histidyl-L-lysine acetate) and maintained in a humidified 5% CO$_2$ incubator at 37 °C, as previously described [10]. The highly transfectable cell line derive from human embryonic kidney 293 cells (HEK293T) were grown in Dulbecco’s modified Eagle’s medium

Penha et al. BMC Cancer (2018) 18:498 Page 2 of 12
**Table 1** Clinicopathologic characteristics of PTC patients (n = 51)

| Variable                          | Category                                               | No. of cases | % of cases |
|-----------------------------------|--------------------------------------------------------|--------------|------------|
| Gender                            | Male                                                   | 10           | 19.6       |
|                                   | Female                                                 | 41           | 80.4       |
| Age                               | ≤40 years                                              | 23           | 45.1       |
|                                   | 41–60 years                                            | 11           | 21.6       |
|                                   | > 60 years                                             | 17           | 33.3       |
| Type of surgery                   | Total or near total thyroidectomy                      | 42           | 82.4       |
|                                   | Partial thyroidectomy                                   | 7            | 13.7       |
|                                   | Others                                                 | 2            | 3.9        |
| Neck dissection                   | Yes                                                    | 27           | 52.9       |
|                                   | No                                                     | 24           | 47.1       |
| Tumour size                       | ≤4 cm                                                  | 43           | 84.3       |
|                                   | > 4 cm                                                 | 8            | 15.7       |
| Pathological stage of primary tumor size (pT) | pT1 and pT2                                         | 22           | 43.1       |
|                                   | pT3 and pT4                                            | 28           | 54.9       |
|                                   | pTx                                                    | 1            | 2.0        |
| Pathological stage of regional lymph node (pN) | pN1                                                  | 30           | 58.8       |
|                                   | pN2                                                    | 3            | 5.9        |
|                                   | pNx                                                    | 18           | 35.3       |
| Pathological stage of distant metastasis (pM) | pM0                                                  | 42           | 82.4       |
|                                   | pM1                                                    | 9            | 17.6       |
| Pathological stage (pTNM)         | pTNM I                                                | 22           | 43.1       |
|                                   | pTNM II                                               | 3            | 5.9        |
|                                   | pTNM III                                              | 4            | 7.8        |
|                                   | pTNM IV                                               | 15           | 29.4       |
|                                   | Unknown                                                | 7            | 13.8       |
| Histopathological classification  | Classic papillary carcinoma                           | 40           | 78.2       |
|                                   | Follicular variant                                     | 5            | 9.8        |
|                                   | Tall cell variant                                      | 2            | 4.0        |
|                                   | Clear cell variant                                     | 1            | 2.0        |
|                                   | Solid variant                                          | 1            | 2.0        |
|                                   | Oncocytic variant                                      | 1            | 2.0        |
|                                   | Others                                                 | 1            | 2.0        |
| Extrathyroid extravasation        | Yes                                                    | 30           | 58.8       |
|                                   | No                                                     | 18           | 35.3       |
|                                   | Unknown                                                | 3            | 5.9        |
| Vascular or angiolymphatic invasion | Yes                                                  | 23           | 45.1       |
|                                   | No                                                     | 22           | 43.1       |
|                                   | Unknown                                                | 6            | 11.8       |
| Morbidity outcome                 | Without recurrence or persistence                      | 21           | 41.2       |
|                                   | Recurrence                                             | 9            | 17.6       |
|                                   | Persistence                                            | 21           | 41.2       |
| Place of outcome                  | Without recurrence or persistence                      | 21           | 41.2       |
|                                   | Local and/or regional lesion only                      | 11           | 21.6       |
|                                   | Distant metastasis only                                | 8            | 15.7       |
(DMEM) (HiMedia Laboratories, Mumbai, India), supplemented with 10% FBS.

Transient transfection assays

**NKX2.5 overexpression**

The NKX2.5 plasmid (7036 bp) (pNKX2.5) contains the full length of NKX2.5 coding region (RefSeq NM_008700), cloned into pcDNA3.1 expression vector (Invitrogen, Carlsbad, California) [11]. PCCL3 cells (1.2 × 10^5) were seeded in 24-well plate and 1 μg of pNKX2.5 or pcDNA3.1 (empty vector, control) were transfected, using Lipofectamine LTX combined with PLUS reagent (Invitrogen, Carlsbad, California) diluted in Ham’s F-12 complete medium. All procedures were performed following the manufacturer’s recommendations.

The efficiency of the transient transfection was evaluated 24 h later by real time PCR with specific oligonucleotides for NKX2.5 gene and immunoblotting analysis using NKX2.5 primary antibody (SAB2101601-Sigma-Aldrich, St. Louis, MO, USA). Concomitantly, PCCL3 cells were transfected with the vector encoding the green fluorescent protein, in order to confirm the transfection efficiency, using the same procedure described above.

**Real time PCR**

Total RNA from cell line was extracted using the RNeasy® Plus Mini Kit (Qiagen, Valencia, California), following the manufacturer’s instructions and subsequently quantified by NanoVue™ Plus spectrophotometer (GE Healthcare, Sweden). Total RNA (0.5–1 μg) was reversely transcribed using MultiScribe™ Reverse Transcriptase (Applied Biosystems, Foster City, CA), in accordance to the manufacturer’s instructions. Reactions for the quantification of mRNA by real-time PCR were performed in an ABI Prism 7500 Sequence Detection System from Applied Biosystems, using 6 μl Maxima SYBR Green qPCR Master Mix (Thermo Scientific, Rockford, IL, USA), 0.5 μl specific oligonucleotides (150 nM), 2.5 μl DEPC water and 3 μl diluted cDNA. The oligonucleotides for real-time PCR were purchased from Applied Biosystems, designed with PrimerQuest software (Integrated DNA Technologies, San Diego, CA, USA) and are listed in Additional file 1. RPL4 was used as internal control. Relative gene expression was determined by subtracting cycle threshold (CT) for the gene of interest from CT for the reference gene, calculated using the 2^ΔΔCT method, as previously described [12] and expressed as relative to control.

**Western blot**

Cells were homogenized in lysis buffer containing 135 mM NaCl, 1 mM MgCl₂, 2.7 mM KCl, 20 mM Tris, pH 8.0, 1% Triton, 10% glycerol and protease and phosphatase inhibitors (0.5 mM Na₂VO₄, 10 mM NaF, 1 mM leupeptin, 1 mM pepstatin, 1 mM okadaic acid, and 0.2 mM phenylmethylsulfonyl fluoride), and then syringed five times. An aliquot was used to determine the concentration of protein by BCA protein assay kit (Pierce, Rockford, IL, USA), as recommended by the manufacturer. Samples were then subjected to SDS/PAGE electrophoresis, transferred to PVDF membranes, and probed with the following antibodies: 1:2000 polyclonal anti-NKX2.5, Sigma-Aldrich; 1:4000 monoclonal anti-GAPDH, Milli-pore; 1:2000 anti-rabbit IgG HRP-linked antibody and 1:4000 anti-mouse IgG HRP-linked antibodies from Cell Signaling. Detection of the proteins was performed using ECL (Thermo Scientific, Rockford, IL, USA).

**Cell viability assay**

As an index of cell viability, we used the commercially available MTT assay (Sigma-Aldrich, St. Louis, MO, USA), according to the recommendations of the manufacturer. The assay is based on the cellular conversion of the tetrazolium salt into formazan that is soluble in culture medium and is directly measured at 490 nm, in a 96-well plate, using a spectrophotometer. Absorbance is directly proportional to the number of living cells in culture. PCCL3 cells were transfected with pcDNA3.1 (control) or pNKX2.5 and 0, 24, 48 and 72 h later MTT assay was performed. Cells were incubated with MTT (0.5 mg/ml) for 3 h at 37 °C in a humidified 5% CO₂ atmosphere. Then, cells were lysed with DMSO (PA). All determinations were made in triplicates and the results were expressed as relative to pcDNA3.1 in initial time (0 h).

**Iodide uptake assay**

Iodide uptake assay was performed as described by Souza et al. [10]. Briefly, PCCL3 cells (1 × 10⁵) were

---

### Table 1 Clinicopathologic characteristics of PTC patients (n = 51) (Continued)

| Variable                        | Category                                      | No. of cases | % of cases |
|---------------------------------|-----------------------------------------------|--------------|------------|
| Both (Local and regional lesion and distant metastasis) | 10 | 19.6 |
| Unknown                        | 1 | 1.9 |
| Lethality within 10 years follow-up | Yes | 8 | 15.7 |
| | No | 43 | 84.3 |
| Cause of death                  | PTC | 6 | 75 |
| | Others | 2 | 25 |
grown in 24-well plates, transfected with pcDNA3 empty vector or pNKX2.5, as described above, and 24 h later they were incubated for 45 min at 37 °C in 1 ml Hank’s balanced salt solution (HBSS) containing 0.1 μCi carrier-free Na\(^{125}\)I and 100 μM NaI. For each experimental condition, a well also received 10 μM KClO
, a competitive inhibitor of NIS, in order to determine the nonspecific radiodiode uptake. After incubation, cells were washed once with ice-cold HBSS and lysed with 0.1 M NaOH, and the radioactivity was determined in a gamma counter (Compu-Gama, 1214, LKB Wallac). An aliquot of each sample was used to determine the protein concentration, using BCA protein assay kit (Pierce, Rockford, IL, USA), as recommended by the manufacturer. Specific iodide uptake value was obtained by subtracting iodide uptake in the absence and in the presence of KClO
 and related to protein concentration. Results were expressed as specific units of iodide accumulation relative to control.

**Extracellular H\(_2\)O\(_2\) production**

Extracellular H\(_2\)O\(_2\) generation was quantified by the Amplex red/horseradish peroxidase assay, which detects the accumulation of a fluorescent oxidized product, as previously described [13]. 24 h after transfection with pcDNA3.1 or pNKX2.5, PCCL3 cells (1 \(\times\) 10\(^5\)) were incubated in Dulbecco’s PBS (D-PBS) containing CaCl\(_2\), MgCl\(_2\), D-glucose (1 mg/ml), iomycin (1 μM), superoxide dismutase (100 U/ml), horseradish peroxidase (0.5 U/ml), and Amplex red (50 μM), and the fluorescence was immediately measured in a microplate reader (VictorX4) for 30 min (excitation wavelength = 530 nm and emission wavelength = 595 nm). Hydrogen peroxide concentration was determined using standard calibration curves and the result was expressed as nmol H\(_2\)O\(_2\) per hour per 10\(^5\) cells. The measurements were made in the presence and in the absence of iomycin, a calcium ionophore, since dual oxidases are calcium-dependent enzymes, and H\(_2\)O\(_2\) generation obtained in the presence of iomycin were subtracted from that obtained in the absence of iomycin.

**DuOx1 promoter activity**

For gene reporter assay, we used the DuOx1 promoter (pDuOx1) plasmid (1 µg), containing the proximal 5′-flanking region of DuOx1 gene and the luciferase reporter gene cloned in the PgL3 vector [14]. It was transiently transfected in combination with wild type or mutated NKX2.5 (Ile\(^{186}\)→Pro) expression vectors [11] or the corresponding empty vector, pcDNA3.1 (500 ng) in HEK293T cells (2 \(\times\) 10\(^5\) cells/well), using Lipofectamine LTX combined with PLUS reagent (Invitrogen, Carlsbad, California), as described above. pRL-CMV, which contains renilla cDNA, was used to correct for transfection efficiency (Promega, Madison, WI, USA). After 24 h, cells were harvested and collected for luciferase and renilla activity by the Dual-Luciferase reporter assay system (Promega, Madison, WI, USA). Luminescence was measured in a Victor X4 Multilabel Plate Reader (PerkinElmer, Norwalk, CT, USA). Results were expressed as relative activity, compared to the control (pcDNA3.1) in each experiment.

**Statistical analysis**

For the statistical analysis, we used the R program (Free Software Foundation, USA) and commercially available software SPSS 20.0 (SPSS Inc., Chicago, IL). Descriptive statistics were used in a preliminary analysis of the relation between baseline variables and outcome events. The PTC-free group was considered as the reference group. The association between the clinic pathological variables and NKX2.5 immunoexpression were analyzed by the Fisher’s exact tests. In addition, the Kaplan-Mayer method was used to evaluate whether the presence of NKX2.5 impacts on morbidity outcomes (persistence/recurrence) and lethality. Tests were considered statistically significant when the p-value was < 0.05.

All in vitro results were expressed as mean ± SEM and were analyzed by the non-parametric Mann Whitney’s test (when comparing two groups) or by the non-parametric Kruskal-Wallis test followed by Dunn’s multiple comparison test (when comparing three or more groups). Statistical analyses were performed using the software Graphpad Prism (Version 5, Graphpad Software Inc., San Diego, USA) and the difference was considered significant when p < 0.05.

**Results**

**NKX2.5 is expressed in PTC samples**

As expected, NKX2.5 was shown to be expressed in human heart, both in cytoplasm and nucleus (Fig. 1a and b), but not in negative control heart (without primary antibody, Fig. 1c and d), what is in accordance to literature data [5]. On the other hand, even though NKX2.5 was described to be transiently expressed only during thyroid organogenesis, until embryonic day 11.5 in mouse 2, normal human thyroid tissue, adjacent to papillary thyroid carcinoma, showed a marked nuclear staining for this transcription factor (Fig. 1e and f), suggesting that NKX2.5 might be re-expressed later in life or that the proximity to cancer environment had an impact on the pattern of expression of neighbor cells.

In papillary thyroid carcinoma, we found variable degrees of NKX2.5 expression, with some patients showing no expression (Fig. 1g and h), while others showed high (Fig. 1i and j) or low (Fig. 1k and l) cytoplasmic expression. Differently from paranodular tissue, NKX2.5 staining in thyroid papillary carcinoma, when present, was...
predominantly found in cytoplasm. Data from all 10 patients are summarized in Additional file 2. Most cases of thyroid papillary carcinoma (8/10) were positive for NKX2.5.

**Overexpression of NKX2.5 promotes a dedifferentiation phenotype in thyroid cells**

In order to investigate the role of NKX2.5 on thyroid function, we overexpressed it in a non-tumoral rat thyroid cell line (PCCL3), which led to an increment in both NKX2.5 mRNA and protein levels (Fig. 2a and b), but did not affect cell viability (Fig. 2c). Even though PCCL3 cells are of rat origin, they were chosen to evaluate the effect of NKX2.5 overexpression because PCCL3 cells keep in vitro important markers of thyroid differentiation (such as ability to trap iodide, synthesize thyroglobulin and TSH-dependency for growth) and they have the same chromosome number (42) of normal rat tissues [15].

Transfection of PCCL3 cells with wild-type NKX2.5 (pNKX2.5) induced a significant reduction of TSH receptor (TSHR) (Fig. 3a) and thyroperoxidase (TPO) (Fig. 3b) mRNA levels, which are important thyroid differentiation markers [16]. Additionally, overexpression of NKX2.5 decreased NIS mRNA levels (Fig. 3c), leading to a reduced iodide uptake in PCCL3 cells (Fig. 3d). Therefore, NKX2.5 seems to have a negative impact in the expression of proteins that are important for thyroid hormone synthesis. These results are in agreement with the disappearance of NKX2.5 just before the beginning of thyroid hormonogenesis [2].

**Differential regulation of dual oxidases by NKX2.5 in PCCL3 cells**

Besides iodide uptake and TPO activity, hydrogen peroxide generation is also important for thyroid hormone biosynthesis [4]. Dual oxidases (DuOx1 and DuOx2) are responsible for thyroid H2O2 generation and the complete glycosylation and activity of these enzymes require the expression of their maturation factors DuOxA1 and DuOxA2 [17]. Thus, we have next decided to study the effect of NKX2.5 overexpression on DuOx expression and activity in PCCL3 cells. In fact, NKX2.5 overexpression in PCCL3 resulted in increased DuOx1 mRNA levels (Fig. 4a), while the maturation factor DuOxA1 mRNA remained unchanged (Fig. 4b). On the other hand...
hand, NKX2.5 overexpression down regulated both DuOx2 (Fig. 4c) and DuOxA2 mRNA levels (Fig. 4d). In addition, extracellular H$_2$O$_2$ generation was stimulated by NKX2.5 (Fig. 4e), in agreement with increased DuOx1 mRNA levels, which is known to be the main DuOx isoform in PCCL3 cells [18]. It is noteworthy that NOX4 mRNA was not detected in PCCL3 cells in our experimental conditions (data not shown).

Since NKX2.5 transfection increased DuOx1 expression and activity in PCCL3 cells, we decided to evaluate whether this effect could occur at the transcriptional level. Thus, we studied the effect of NKX2.5 (wild type or mutant) overexpression on DuOx1 promoter. As shown in fig. 4f, NKX2.5 stimulated DuOx1 promoter (pDuOx1) when compared to basal promoter activity. Moreover, transfection of Ile$^{183}$$\rightarrow$Pro NKX2.5 mutant (Nkx2.5 mut), which keeps homodimerization function but does not bind DNA [11], did not have the same effect (Fig. 4f), suggesting that interaction with DNA is essential for DuOx1 promoter regulation by NKX2.5. Thus, the effect of NKX2.5 regulating DuOx1 seems to occur at the transcriptional level.

**The expression of NKX2.5 predicts better prognosis in PTC samples**

We then wondered whether the expression of NKX2.5 could impact on the outcome of the patients with PTC. The study population was predominantly composed of females (89.4%), with a mean age of 48 years (ranging from 18 to 81 years). Most patients underwent surgical treatment of total or near total thyroidectomy (82.4%). Tumors smaller than 4 cm (84.3%) and in pathological stage I (43.1%) were predominant. Twenty-one (41.2%) cases had persistent disease and nine cases (17.6%) with recurrence were identified. According to histopathological classification, classic papillary carcinomas (78.7%) were predominant. Eight out of 51 cases (15.7%) died as a result of PTC and/or from any other cause, according to the cancer death registry of the hospital (Table 1). The expression of NKX2.5 was observed in 53% of the cases, being 31.4% with low score in the tumor (Table 2). The presence of NKX2.5 in the primary thyroid tumor was not associated to lethality or morbidity in 10 years. According to the outcome, negative score of NKX2.5 was related to persistence ($p = 0.013$) and pathological stage of primary tumor sizes pT1 and pT2 ($p = 0.029$). All the details about the association between NKX2.5 expression and patients’ data are provided in Table 2. Thus, our data suggest that the expression of NKX2.5 in PTC samples is associated to a better prognosis for the patients.

**Discussion**

The regulation of cell proliferation and differentiation is crucial for both normal development and carcinogenesis, therefore it is expected that genes critical for thyroid organogenesis could also play a role in thyroid cancer [19]. In this study, we reported that NKX2.5 is highly expressed in PTC samples. The expression of NKX2.5 has been described in a variety of tumors, being correlated to a malignant transformation of the neoplastic cells [6–8]. In agreement with that, we have observed a nuclear immunostaining of NKX2.5 in normal adjacent thyroid tissue, which suggest that the expression of this transcription factor could be an early event of thyroid carcinogenesis. Accordingly, our data revealed that NKX2.5 overexpression decreased mRNA levels of the
thyroid differentiation markers (TPO, NIS and TSH receptor) in normal thyroid cells, which reinforces our hypothesis that NKX2.5 promotes a dedifferentiation phenotype in thyroid cells. Above all, we have found a reduction in iodide uptake, which could be due to oxidative damage of NIS, since NKX2.5 overexpression induced an increment in hydrogen peroxide generation, and/or to a direct effect of NKX2.5 downregulating NIS. It is important to underline that NIS regulation is of great relevance not only for thyroid physiology but also for the management of thyroid diseases, since radioiodine therapy is used to treat thyroid cancer and the loss of NIS is associated with poor prognosis of thyroid cancer patients [20, 21].

Elevated amounts of ROS have been related to genomic instability and tumorigenesis in thyroid cells [22] and H$_2$O$_2$-generating activity of DuOx1 seems to contribute to these events [23]. Overexpression of NKX2.5 in PCCL3 cells resulted in enhanced H$_2$O$_2$ generation, which seems to be due to increased DuOx1 activity, since mRNA levels of DuOx1 were upregulated by NKX2.5 and NOX4 mRNA was not detected in PCCL3 in our assay conditions. Even though DuOx2 and DuOxA2 mRNA levels were reduced in cells transfected with NKX2.5, it is well known that DuOx1 is the main source of H$_2$O$_2$ in PCCL3 cells [18]. Interestingly, our results suggest that NKX2.5 upregulates DuOx1 at the transcriptional level, leading to increased ROS production and thus reinforcing the idea that NKX2.5 could predispose thyroid cells to carcinogenesis.

Herein, we have found a predominantly cytoplasmic expression of NKX2.5 in PTC samples. NKX2.5 activation and subcellular localization have been shown to be regulated by factors such as matrix stiffness and sumoylation [24, 25]. Since sumoylation machinery, which is known to activate NKX2.5 [25], is reduced in PTC [26], we hypothesize that the cytoplasmic localization of NKX2.5 in PTC could be due to a reduction in NKX2.5 sumoylation.

Changes in DNA methylation have been shown to induce tumor initiation and progression [27], and PTC exhibits global hypomethylation when compared to normal thyroid [28]. Interestingly, the expression of NKX2.5 is regulated by methylation of the promoter region [29].
Fig. 4 (See legend on next page.)
and hence, an epigenetic dysregulation of NKX2.5 promoter region might be a plausible mechanism underlying NKX2.5 overexpression in PTC samples.

Although the vast majority of PTC patients has good prognosis, 1/3 of all cases persist or relapse [30]. In our study, the absence of NKX2.5 was associated to the persistence of PTC, suggesting that NKX2.5 expression does not seem to contribute to clinic aggressiveness of the disease. Furthermore, treated patients who express NKX2.5 have lower rate of persistence/recurrence, indicating that its expression might be associated to a less aggressive tumor behavior. So, NKX2.5 could be useful as a molecular target to help predicting the outcome of PTC patients, clinically relevant information to decide the best therapeutic approach. Moreover, in PTC patients, the absence of NKX2.5 was associated to the pathological stage of primary tumor size pT1 and pT2, despite the fact that PCCL3 cell viability was pathological stage of primary tumor size pT1 and pT2, but later NKX2.5 have to disappear before thyroid differentiation, as shown in PCCL3 overexpressing NKX2.5 and hence, an epigenetic dysregulation of NKX2.5 promoter region might be a plausible mechanism underlying NKX2.5 overexpression in PTC samples.

Our findings also unravel NKX2.5 as promising molecular target that could help to predict patients’ outcomes. Thus, NKX2.5 could have a similar effect, contributing for thyroid cancer initiation but not for progression.

Conclusions
We have reported for the first time that NKX2.5 is expressed in PTC and regulates differentiation, iodide uptake and extracellular ROS generation in thyroid cells. Our findings also unravel NKX2.5 as promising molecular target that could help to predict patients’ outcomes.

Table 2: Clinicopathologic characteristics and immunohistochemical expression of NKX2.5 of the PTC tumor (N = 51). Data were analyzed by Fisher’s exact test

| Variable                        | Category                   | Score of NKX2.5 | p Value |
|---------------------------------|-----------------------------|-----------------|---------|
|                                 | NNX2.5 expression           |                 |         |
|                                 | Negative                    | 24 (47.1%)      |         |
|                                 | Positive                    | 0 (0.0%)        |         |
|                                 | Outcome                     |                 |         |
|                                 | Without recurrence or persistence | 7 (13.7%)   | 0.013   |
|                                 | Recurrence                  | 3 (5.9%)        |         |
|                                 | Persistence                 | 14 (27.5%)      |         |
| Pathological stage of primary tumor size (pT) | pT1 and pT2       | 14 (27.5%)      | 0.029   |
|                                 | pT3 and pT4                 | 10 (19.6%)      |         |
|                                 | pTx                         | 0 (0.0%)        |         |

Negative score of NKX2.5 was related to persistence (p = 0.013) and pathological stage of primary tumor sizes pT1 and pT2 (p = 0.029).
Abbreviations
CT: Cycle threshold; DuOx: Dual oxidase; NIS: Sodium-iodide symporter; PBS: Phosphate-buffered saline; PTC: Papillary thyroid carcinoma; RA: Radioactive iodine; ROS: Reactive oxygen species; Tg: Thyroglobulin; TPO: Thyroperoxidase; TSHR: Thyrotropin receptor

Acknowledgements
We are grateful for the technical assistance of Norma Lima de Araújo Faria, Advaldo Nunes Bezerra, Wagner Nunes Bezerra, Walter Nunes Bezerra and José Humberto Tavares de Abreu.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
All authors have contributed significantly, and all authors agree with the content of the manuscript. RCC participated in acquisition, analysis, and interpretation of data for the work, revised and wrote the work, gave the final approval of the version to be published, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. LAB, FRR, TPC, MCS, DPC, and DPC participated in acquisition, analysis, and interpretation of data for the work, revised the work, gave the final approval of the version to be published, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors have read and approved the manuscript.

Ethics approval and consent to participate
All procedures performed involving human participants were in accordance with the ethical standards of the INCA HC (National Institute of Cancer, São Paulo, Brazil). All procedures performed involving human participants were in accordance with the ethical standards of the INCA HC (National Institute of Cancer, São Paulo, Brazil). All procedures performed involving human participants were in accordance with the ethical standards of the INCA HC (National Institute of Cancer, São Paulo, Brazil).

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Laboratório de Fisiologia Endócrina Doris Rosenthal, IBCCF, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 2Programa de Carcinogênese Molecular - Centro de Pesquisas (CPC), Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA), Rio de Janeiro, Brazil. 3Departamento de Patologia, Faculdade de Medicina, Universidade Federal Fluminense, Rio de Janeiro, Brazil. 4Centro de Estudos da Saúde do Trabalhador e Ecologia Humana- CESTEH-ENSP/FIOCRUZ, Rio de Janeiro, RJ, Brazil. 5Laboratório de Radiobiologia Molecular, IBCCF, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 6Campus Duque de Caxias/NUPMEX, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Received: 13 June 2017 Accepted: 18 April 2018
Published online: 02 May 2018

References
1. Tanaka M, Schinke M, Liao HS, Yamasaki N, Izumo S. NKO2.5 and Nko2.6, homologs of Drosophila trimm, are required for development of the pharynx. Mol Cell Biol. 2001;21:4391–8.
2. Dentice M, Cordeddu V, Rosica A, Ferrara AM, Santarpia L, Salvatore D, et al. Missense mutation in the transcription factor NKX2-5: a novel molecular event in the pathogenesis of thyroid dysgenesis. J Clin Endocrinol Metab. 2006;91:1428–33.
3. De Felice M, Di Lauro R. Thyroid development and its disorders: genetics and molecular mechanisms. Endocr Rev. 2004;25:722–46.
4. Milenkovic M, De Deken X, Jin L, De Felice M, Di Lauro R, Dumont JE, et al. Duox expression and related H2O2 measurement in mouse thyroid: onset in embryonic development and regulation by TSH in adult. J Endocrinol. 2007;192:615–26.
5. Lints TJ, Parsons LM, Hartery L, Lyons I, Harvey RP. Nkx-2.5: a novel murine homeobox gene expressed in early heart progenitor cells and their myogenic descendants. Development. 1993;119:419–31.
6. Nagel S, Kaufmann M, Drexl HG, MacLeod RA. The cardiac Homeobox gene NKX2-5 is deregulated by juxtaposition withBCL11B in pediatric T-ALL cell lines via a novel 15q14-q21(q31.1;q32.2). Cancer Res. 1993;63:5329–34.
7. Hwang C, Jiang S, Choi DK, Kim S, Lee JH, Lee Y, Kim CD, Lee JH. The role of NKX2.5 in keratinocyte differentiation. Ann Dermatol. 2009;21:376–81.
8. Shibata K, Kajiyama H, Yamamoto E, Terauchi M, Ino K, Nawa A, Kikkawa F. Establishment and characterization of an ovarian yolk sac tumor cell line reveals possible involvement of NKX2.5 in tumor development. Oncology. 2008;74:104–11.
9. de Castro TP, Waissmann M, Simões TC, de Mello RC, Carvalho DP. Predictors for papillary thyroid carcinoma persistence and recurrence: a retrospective analysis with a 10-year follow-up cohort study. Clin Endocrinol (Oxf). 2016;85:465–74.
10. Souza EC, Padrão AS, Braga WM, Andrade BM, Vaisman M, Nasciuti LE, et al. MITOR downregulates iodide uptake in thyrocytes. J Endocrinol. 2010;206:113–20.
11. Kaahara H, Usheva A, Ueyama T, Askì H, Horikoshi N, Izumo S. Characterization of homo- and heterodimerization of cardiac Csx/NKX2.5 homeprotein. J Biol Chem. 2001;276:4570–5.
12. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3:1101–8.
13. Fortunato RS, Braga WM, Orenzi VH, Rodrigues DC, Andrade BM, Miranda-Alves L, et al. Sexual dimorphism of thyroid reactive oxygen species production due to higher NADPH oxidase 4 expression in female thyroid glands. Thyroid. 2013;23:111–9.
14. Pachucki J, Wang D, Cristofe D, Miot F, Duron J, Dufour S, et al. Role of the thyroid-stimulating hormone receptor signaling in development and differentiation of the thyroid gland. Proc Natl Acad Sci U S A. 2002;99:15462–7.
15. Grasberger H, Refetoff S. Identification of the maturation factor for dual oxidase. Mol Cell Endocrinol. 2004;214:53–62.
16. Fusco A, Berlingieri MT, Di Fiore PP, Portella G, Vecchio G. One-step PCR amplification and analysis of single nucleotide polymorphisms using a novel t(5;14)(q35.1;q32.2). Cancer Res. 1993;63:5329–34.
17. Postiglione MP, Parlatò R, Rodríguez-Mallón A, Rosica A, Mitbracker P, Maresca M, Mairans RC, Davies TF, Zannini MS, De Felice M, Di Lauro R. The role of the thyroid-stimulating hormone receptor signaling in development and differentiation of the thyroid gland. Proc Natl Acad Sci U S A. 2002;99:15462–7.
18. Grasberger H, Refetoff S. Identification of the maturation factor for dual oxidase. Evolution of an eukaryotic open reading frame in the tPOD gene. J Biol Chem. 2001;276:4570–80.
19. Smirnov A, Miot F, De Deken X, Pouchot J, Miquel J, Izumo S. NKX2-5 is expressed in the thyroid gland. J Cell Biol. 1995;129:673–87.
20. Dohán O, De la Vieja A, Paroder V, Riedel C, Antani M, Reed M, Ginter CS, Carrasco N. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev. 2003;24:48–77.

21. Carvalho DP, Ferreira AC. The importance of sodium/iodide symporter (NIS) for thyroid cancer management. Arq Bras Endocrinol Metabol. 2007;51:672–82.

22. Ameziane-El-Hassani R, Boufraqech M, Lagente-Chevallier O, Weyemi U, Talbot M, Métivier D, Courton F, Bidart JM, El Maibri M, Schlumberger M, Dupuy C. Role of H2O2 in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells. Cancer Res. 2010;70:4123–32.

23. Ameziane-El-Hassani R, Talbot M, de Souza Dos Santos MC, Al Ghuzlan A, Hartl D, Bidart JM, et al. NADPH oxidase DUOX1 promotes long-term persistence of oxidative stress after an exposure to irradiation. Proc Natl Acad Sci U S A. 2015;112:5051–6.

24. Dingal PC, Bradshaw AM, Cho S, Raab M, Buxboim A, Swift J, Discher DE. Fractal heterogeneity in minimal matrix models of scars modulates stiffness in stem-cell responses via nuclear export of a mechanorepressor. Nat Mater. 2015;14:551–60.

25. Wang J, Zhang H, Iyer D, Feng XH, Schwartz RJ. Regulation of cardiac specific nkk2.5 gene activity by small ubiquitin-like modifier. J Biol Chem. 2008;283:23235–43.

26. Tuccilli C, Baldini E, Sorrenti S, Di Gioia C, Bosco D, Ascoli V, et al. Papillary thyroid cancer is characterized by altered expression of genes involved in the sumoylation process. J Biol Regul Homeost Agents. 2015;29:655–62.

27. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11:726–34.

28. Ellis RJ, Wang Y, Stevenson HS, Boufraqech M, Patel D, Nilubol N, et al. Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype. J Clin Endocrinol Metab. 2014;99:E329–37.

29. Sheng W, Qian Y, Wang H, Ma X, Zhang P, Diao L, et al. DNA methylation status of NKX2-5, GATA4 and HAND1 in patients with tetralogy of fallot. BMC Med Genet. 2013;6:46.

30. Bhardwaj PR, Mishra A, Agarwal G, Agarwal A, Pradhan PK, Gambhir S, Verma AK, Mishra SK. Long-term outcome of differentiated thyroid carcinoma: experience in a developing country. World J Surg. 2010;34:40–7.

31. Nagel S, Venturini L, Przybylski GK, Grabarczyk P, Schmidt CA, Meyer C, Drexler HG, Macleod RA, Scherr M. Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2009;50:101–8.

32. Melo M, Garpar da Rocha A, Batista R, Vinagre J, Martins MJ, Costa G, Ribeiro C, Carlinho F, Leite V, Lobo C, Cameselle-Teijeiro JM, Cavadas B, Pereira L, Sobrinho-Simões M, Soares P. TERT, BRAF, and NRAS in primary thyroid cancer and metastatic disease. J Clin Endocrinol Metab. 2017;102(6):1898–907.
